Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy

Jun Dang1, Guang Li1*, Shuang Zang2, Shuo Zhang1 and Lei Yao1

Abstract

Background: The rate of radiation pneumonitis (RP) for patients receiving chemoradiotherapy has been various across studies. Whether it is related to different chemotherapy schedules used in combination with radiation therapy were evaluated in this study. New factors associated with RP were also investigated.

Methods and materials: A total of 369 consecutive patients with Stage III non small cell lung cancer treated with chemoradiotherapy were followed after radiotherapy (RT). Among them 262 patients received concurrent chemoradiotherapy followed by consolidation chemotherapy and 107 patients received only sequential chemotherapy after RT. RP was graded according to Common Terminology Criteria for Adverse Events version 4.0.

Results: The rate of grade $\geq 2$ were 39.7%, 31% and 33.6% in the concurrent DP (docetaxel/cisplatin), concurrent NP (vinorelbine/cisplatin) and sequential group, and grade $\geq 3$ RP were 18.4%, 9.5%, and 11.2% respectively. The rate of grade $\geq 3$ RP was significantly higher in concurrent DP group than that in concurrent NP group (p = 0.04). RP occurred earlier in concurrent DP group than that in the other two groups. There were no significant differences in response rate among the three groups. In the multivariate analysis, age (OR = 1.99, p = 0.038 and OR = 8.90, p < 0.001), chemotherapy schedule (OR = 1.45, p = 0.041 and OR = 1.98, p = 0.013), mean lung dose(OR = 1.42, p < 0.001 and OR = 1.64, p < 0.001), and planning target volume(OR = 1.004, p = 0.001 and OR = 1.005, p = 0.021) were predictors for both grade $\geq 2$ and grade $\geq 3$ RP. Response to treatment was a new predictor for grade $\geq 3$ RP only (OR = 4.39, p = 0.034).

Conclusions: Response to treatment was found to be a new predictor for grade $\geq 3$ RP. Compared to concurrent NP schedule, concurrent DP schedule achieved similar response to treatment but resulted in a higher risk of grade $\geq 3$ RP.

Keywords: Non-small cell lung cancer, Radiation pneumonitis, Predictor, Concurrent chemoradiotherapy, Sequential chemoradiotherapy

Background

Approximately 30% of patients with non small cell lung cancer (NSCLC) are diagnosed at a locally advanced stage. In unresectable locally advanced lung cancer (LA-NSCLC), compared to radiation therapy (RT) alone, the addition of cisplatin based sequential chemotherapy to radiation therapy resulted in modest improvement in survival [1,2]. Concurrent cisplatin based chemoradiotherapy showed consistent improvement in survival compared with sequential chemoradiotherapy [3-5]. Concurrent chemoradiotherapy (CCRT) has been regarded as the standard treatment for unresectable LA-NSCLC patients with good performance status.

Treatment-related acute pulmonary toxicity for patients receiving chemoradiotherapy has been various across studies (4.8% to 47%), and various chemotherapy drugs (e.g., taxanes, pemetrexed, irinotecan, gemcitabine) were used (Table 1). Whether the differences in risk of radiation

* Correspondence: gl1963516@hotmail.com
1Department of Radiation Oncology, The First Hospital of China Medical University, No.155 Nanjing Road, Heping District, Shenyang 110001, China
Full list of author information is available at the end of the article
© 2014 Dang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pneumonitis (RP) are related to different chemotherapy drugs or chemotherapy schedules used in combination with RT need further investigated.

In this study, we evaluated the risk of RP in patients with Stage III NSCLC treated with concurrent or sequential chemoradiotherapy respectively. We also analyzed clinical and dose-volume factors correlated with the development of RP.

Methods and materials
Patients
From October 2009 through August 2013, 427 consecutive patients with stage III NSCLC received concurrent or sequential chemoradiotherapy at the Radiotherapy Department of The First Hospital of China Medical University. These patients were recruited into our study. Patients were staged according to the new staging system initiated by the International Association for the Study of Lung Cancer in 2009 [14]. Patients were excluded if they were treated with inconsistent doses per fraction (n = 12), treated with inconsistent chemotherapy schedules or drugs (n = 28), or a total radiation dose less than 50 Gy (n = 17). Thus, 369 patients were followed up prospectively after RT was completed.

Radiation therapy
All of the patients underwent three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT). Treatments planning computed tomography (CT) scans with slices 5 mm thick were obtained from the mandible to the lower edge of the liver before RT. The gross tumor volume (GTV) included the primary disease as well as any involved regional lymph nodes, which were defined as those with a short-axis diameter of at least 1 cm on CT scan or with a short-axis diameter of less than 1 cm but with high fluorodeoxyglucose (FDG) uptake on PET-CT scan. The clinical target volume (CTV) was defined as the GTV plus a 0.6 cm-0.8 cm margin. The planning target volume (PTV) was the CTV with 0.5–1.0 cm margin. The prescribed dose was 60–66 Gy in 2.0-2.2 Gy daily fractions. Five fractions a week were usually used.

Chemotherapy
262 patients received concurrent chemoradiotherapy, and 107 patients received sequential chemoradiotherapy. There were two chemotherapy regimens (DP and NP) for the concurrent group. Concurrent DP regimen consisted of 20–25 mg/m²/d of cisplatin on days 1–3 and 65–70 mg/m²/d of docetaxel on day 1; Concurrent NP regimen consisted of 20–25 mg/m²/d of cisplatin on days 1–3 and 20 mg/m²/d of vinorelbine on days 1 and 5. Chemotherapy was initiated simultaneously with RT, 1 to 2 cycles was concurrently administered with radiotherapy and 2 to 3 cycles was administered within 4 weeks of completing RT (for 28% of patients in concurrent NP group, NP regimen was concurrently administered with radiotherapy, but DP regimen was administered in followed consolidation chemotherapy). The chemotherapy regimen for sequential group was DP (20–25 mg/m²/d of cisplatin on days 1–3 and 70–75 mg/m²/d of docetaxel on day 1); chemotherapy was initiated 2 to 4 weeks after RT, 3 to 4 cycles was administered, and every 3–4 week a cycle.

Dose-volume histogram (DVH) parameters
The total normal lung volume was defined as the total lung volume minus the primary CTV and the volume of the trachea and main bronchi. The following parameters were extracted for modeling: V20 (total lung volume receiving ≥20 Gy), mean lung dose (MLD), mean heart dose (MHD) and planning target volume (PTV).

Evaluation and follow-up
Early RP and late lung fibrosis are different stages of radiation-induced lung injury. Early RP usually occurs 1 to 6 months after RT, whereas late lung fibrosis usually

### Table 1 Results of RP risk in clinical studies for CCRT

| Study            | Patients (n) | Treatment schedule                                      | RT dose (Gy) | RP          |
|------------------|-------------|--------------------------------------------------------|--------------|-------------|
| Belani et al. [6] | 74          | PC + RT followed by PC                                  | 63           | Grade ≥3 16%|
| Gandara et al. [7] | 83          | PE + RT followed by docetaxel                           | 61           | Grade ≥3 7% |
| Fournel P et al. [3] | 100        | PE + RT followed by NP                                  | 60           | Grade ≥3 5% |
| Xu Y et al. [8]   | 21          | pemetrexed/cisplatin + RT followed by pemetrexed/cisplatin | NR           | Grade ≥3 4.8%|
| Bastos BR et al. [9] | 32         | carboplatin/irinotecan + RT followed by docetaxel       | 63           | Grade ≥2 42%|
| Eroglu C et al. [10] | 93         | DP + RT followed by DP                                  | 66           | Grade ≥3 9% |
| Phernambucq EC et al. [11] | 83        | cisplatin/gemcitabine + RT followed by PE              | 44-66        | Grade ≥3 7.9%|
| Wang S et al. [12] | 223         | PC + RT followed by PE                                  | 63           | Grade ≥3 32%|
| Onishi H et al. [13] | 32         | weekly docetaxel                                        | 60-66        | Grade ≥3 47%|

RP, radiation pneumonitis; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; PC, cisplatin/paclitaxel; PE, cisplatin/etoposide; DP, docetaxel/cisplatin.
occurs 6–24 months after RT. Because we were interested in early RP, we used six months as the cut-off for diagnosis.

Patients were evaluated by radiation oncologists weekly during radiation, and once a month until six months after RT. A chest CT scan was performed at each follow-up evaluation after completion of radiotherapy. A diagnosis of RP was made with consensus by at least two radiation oncologists based on clinical symptoms, with or without radiographic infiltrate changes. Findings on a CT image of RP include a diffuse haziness or fuzziness in the areas of the irradiated lung, which may coalesce to a form a relatively sharp edge corresponding to the shape and size of the radiation field. These radiographic changes in RP may also reveal outside the radiation field. The symptoms of RP are dry cough, low-grade fever, chest pain, and shortness of breath. Cases difficult to diagnose were referred to respiratory or circulation physicians to exclude other diseases. Patients with a diagnosis of grade ≥ 2 RP were required to have an immediate intervention, including oral or intravenous steroids, oxygen, and antibiotics. Grading was conducted according to Common Terminology Criteria for Adverse Events version 4.0 [15].

Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate treatment response 4–6 weeks after the completion of the treatments.

**Statistical analysis**

Grade2 or above RP were counted as events. Statistical analysis was performed using SPSS 13.0 statistical software (Chicago, IL). Univariate analysis was performed to evaluate the influence of patient characteristics and dose-volume variables on RP risk. The independent samples t-test, analysis of variance or the χ²-test, were used for univariate analysis. Multivariate analysis was performed using logistic regression model (enter method) containing all variables that attained or trended toward univariate statistical significance (p ≤ 0.3) in Table 2. The receiver operating characteristic (ROC) curve was used to identify the c-statistics for each dose-volume variable and the models. The correlation between dose-volume variables was tested with Pearson Correlation Coefficient. All statistical tests were 2-sided and p ≤ 0.05 was considered statistically significant.

**Results**

Four patients died of grade 5 RP (three in concurrent DP group, and one in concurrent NP group). All other patients were successfully followed up through the end point of six months after RT.

| Characteristics | No. of patients |
|-----------------|-----------------|
| Sex (male/female) | 263(71%)/106(29%) |
| Age (≥70/<70) | 117(32%)/252(68%) |
| Performance status (0/1/2) | 144(31%)/244(66%)/11(3%) |
| Stage (IIA/IIIB) | 234(63%)/135(37%) |
| Pathology (squamous/adenocarcinoma/other) | 229(62%)/119(32%)/21(6%) |
| CTV location | 136(37%)/126(34%)/107(29%) |
| Smoking history (yes/no) | 230(62%)/139(38%) |
| Response (CR + PR/others) | 280(76%)/89(24%) |
| RT (3D-CRT/IMRT) | 288(78%)/81(22%) |
| Chemotherapy schedule (concurrent DP/concurrent NP/sequential) | 229(62%)/119(32%)/21(6%) |
| Smoking history (yes/no) | 230(62%)/139(38%) |
| Smoking history (yes/no) | 230(62%)/139(38%) |
| Smoking history (yes/no) | 230(62%)/139(38%) |

*CTV*, clinical target volume; *CR*, complete response; *PR*, partial response; *DP*, docetaxel/cisplatin; *NP*, vinorelbine/cisplatin; *3D-CRT*, three-dimensional conformal radiotherapy; *IMRT*, intensity-modulated radiotherapy.

**Response to treatment**

The response rates (CR + PR) were 78.7% in concurrent DP, 77% in concurrent NP, and 71% in sequential group respectively, which were not significantly different (P = 0.585).

**Evaluation of RP**

RP occurred earlier in concurrent DP group (2.4 ± 1.1 months after RT) than in concurrent NP (2.9 ± 1.2 months after RT) and sequential group (3.2 ± 1.2 months after RT) (p < 0.05 for each comparison).

The rate of grade ≥ 2 were 39.7%, 31% and 33.6% in the concurrent DP, concurrent NP and sequential group, and grade ≥ 3 RP were 18.4%, 9.5%, and 11.2% respectively. The rate of grade ≥ 3 RP was significantly higher in concurrent DP group than that in concurrent NP group (p = 0.04).

**Patient characteristics**

Patient characteristics were listed in Table 2. The results of univariate analysis were shown in Table 3. The results of the multivariate analysis suggested that age and chemotherapy schedule were predictors for both grade ≥ 2 (OR = 1.99, p = 0.038; OR = 1.45, p = 0.041) and grade ≥ 3 RP (OR = 8.90, p = 0.000; OR = 1.98, p = 0.013). Response to treatment was a predictor for grade ≥ 3 RP only (OR = 4.39, p = 0.034) (Table 4).

**Dose-volume factors**

In univariate analysis, the dose-volume variables of V20, MLD, MHD and PTV were all significantly associated with RP (p = 0.000 for each comparison) (Table 3). C-statistics for each dose-volume variable were shown in Table 5. Due to the linear correlation between MLD and...
V20 (r = 0.851, p = 0.000), and MLD had the higher c-statistic than V20 (grade ≥ 2: 0.838 vs. 0.808; grade ≥ 3: 0.897 vs. 0.827), V20 was removed from the logistic regression model. MLD, MHD and PTV were included in the multivariate logistic regression analysis. The results of the multivariate analysis suggested that MLD and PTV were predictors for both grade ≥ 2 (OR = 1.42, p < 0.001 and OR = 1.004, p = 0.001) and grade ≥ 3 RP (OR = 1.64, p < 0.001 and OR = 1.005, p = 0.021) (Table 4). The c-statistic was 0.86 for the Grade ≥ 2 model and 0.94 for the Grade ≥ 3 model, indicating good discrimination.

Discussion

Combination of chemotherapy and RT has been well reported increasing the risk of pulmonary injury, either sequential [16] or concurrent [12,13]. Weekly docetaxel with concurrent conventional radiotherapy resulted in 47% grade ≥ 3 RP [13]; Carboplatin plus taxanes with concurrent 3D-CRT resulted in 32% grade ≥ 3 RP [12]. However, there are also inconsistent results. PE regimen showed 5% grade ≥ 2 RP [3], and pemetrexed plus carboplatin regimen showing 4.8% grade ≥ 3 RP [8] with concurrent 3D-CRT in two Phase III trials. Data from a large meta-analysis of predictors of RP showed that concurrent carboplatin/paclitaxel regimen was associated with a high risk of RP compared with concurrent cisplatin/etoposide regimen [17]. In this study, we compared the risk of RP among concurrent DP, concurrent NP and sequential group respectively. Our data showed a higher rate of grade ≥ 3 RP for concurrent DP schedule (18.4%) than that for concurrent NP schedule (9.5%)(p < 0.05), while the risk of RP for sequential schedule was moderate (11.2% for grade ≥ 3). Chemotherapy schedule was an independent predictor for grade ≥ 3 RP (OR = 1.98, p = 0.013). The results above suggested that differences in RP risk across studies might be related to different chemotherapy schedule or drugs used in chemoradiotherapy. Thus care should be taken when chemotherapy schedule or drugs are selected in combination with RT to ensure that treatment toxicities do not overwhelm the potential benefits of treatment.

Table 3 Demographic and tumor characteristics and dose-volume factors of patients by RP status

| Variables | Grade 0-1 (n = 240) | Grade 2 (n = 80) | Grade ≥ 3 (n = 49) | p-value |
|-----------|---------------------|-----------------|---------------------|---------|
| Sex (male/female) | 174/66 | 57/23 | 32/17 | 0.598 |
| Age (≥70/<70) | 72/168 | 22/58 | 23/26 | 0.044 |
| Performance status (0/1/2) | 74/157/9 | 24/55/1 | 16/32/1 | 0.808 |
| Stage (ⅢA/ⅢB) | 159/81 | 46/34 | 29/20 | 0.299 |
| Pathology (squamous/adenocarcinoma/others) | 145/81/14 | 54/23/3 | 30/15/4 | 0.723 |
| CTV location | | | | |
| Left/right | 115/123 | 48/32 | 30/19 | 0.083 |
| Upper/lower | 164/76 | 48/32 | 23/26 | 0.013 |
| Smoking history (Y/N) | 153/87 | 49/31 | 28/21 | 0.668 |
| Response (PR + CR/others) | 173/67 | 62/18 | 45/4 | 0.012 |
| RT (3D-CRT/IMRT) | 189/51 | 63/17 | 36/13 | 0.708 |
| Chemotherapy schedule (concurrent DP/concurrent NP/sequential) | 82/87/71 | 29/27/24 | 25/12/12 | 0.268 |
| PTV | 396.67 ± 107.18 | 460.59 ± 105.02 | 514.92 ± 98.47 | 0.000 |
| V20 | 0.28 ± 0.09 | 0.37 ± 0.09 | 0.43 ± 0.10 | 0.000 |
| MLD | 14.15 ± 3.26 | 17.71 ± 3.28 | 21.40 ± 3.48 | 0.000 |
| MHD | 15.24 ± 7.16 | 20.33 ± 6.36 | 22.31 ± 5.62 | 0.000 |

Table 4 C-statistics for dose-volume variables

| Variables | Grade ≥ 2 | Grade ≥ 3 |
|-----------|-----------|-----------|
| c-statistics | 95% CI | c-statistics | 95% CI |
| V20 | 0.808 | 0.761-0.855 | 0.827 | 0.771-0.883 |
| MLD | 0.838 | 0.794-0.881 | 0.897 | 0.854-0.939 |
| MHD | 0.727 | 0.674-0.779 | 0.725 | 0.655-0.796 |
| PTV | 0.720 | 0.667-0.774 | 0.757 | 0.692-0.822 |

RP, radiation pneumonitis; CTV, clinical target volume; PTV, planning target volume; V20, lung volume receiving ≥ 20 Gy; MLD, mean lung dose; MHD, mean heart dose; CR, complete response; PR, partial response; DP, docetaxel/cisplatin; NP, vinorelbine/cisplatin; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy.
There were no significant differences in the response rate among concurrent DP (78.7%), concurrent NP (77%) and sequential group (71%) in this study (P = 0.585). However, it was interesting to note a significantly higher rate of RP for patients with good response to treatment (CR or PR) than others (p < 0.05) (Table 3), and the response to treatment was an independent predictor for grade ≥3 RP in Multivariate analysis (OR = 4.39, p = 0.034) (Table 4). To our knowledge, no study has been reported to analyze the correlation between the response to treatment and RP. How to explain the result? Most of our patients were with relatively large tumor size (T3), and treated with concurrent DP or concurrent NP RT. Chemotherapy drugs thought to be radiosensitization might lead to rapid response to treatment during process of RT. If treatment planning were not modified in time, the original GTV would contain part of lung leading to higher dose to larger volume of lung. If so, modifying treatment planning in time during process of RT for patients receiving concurrent chemoradiotherapy would become definitely necessary.

MLD and age were predictors for RP in this study, which were consistent with the literature. Results from studies about the correlation between PTV and the risk of RP remain inconsistent [18,19]. It might be related to differences in total lung volume of different patients; that is, a lower percentage of lung would be irradiated in patients with a larger lung volume and a higher percent of lung would be irradiated in patients with a smaller lung volume when their PTV were equal. PTV was a predictor for both grade ≥2 and grade ≥3 RP in our study, however, the correlation was weak (OR = 1.004 and OR = 1.005, respectively) (Table 4).

Rodrigues G, et al. [20] performed a systematic review of the predictive ability of various dose–volume variables (V_{dose}, MLD) for RP and found that most studies did show an association between dose–volume variables and RP risk, however, the predictive ability was generally poor. In this study, dose–volume variables such as MLD and V20 had the higher c-statistics for Grade ≥2 or Grade ≥3 RP, indicating good discrimination (Table 5).

In this study, RP occurred earlier in concurrent DP group than that in concurrent NP or sequential group (p < 0.05). It was probably due to damage to lung by docetaxel used in concurrent RT process.

Conclusions
Compared to concurrent NP schedule, concurrent DP schedule achieved similar response to treatment but resulted in a higher risk of RP. Besides age, PTV, and MLD, response to treatment and chemotherapy schedule were found to be new predictors for RP.

Consent
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JD and GL are lead authors who participated in manuscript drafting, table creation, and manuscript revision. SZ performed statistical analyses. SZ participated in the clinical coordination and aided in data collection. LY is the dosimetrist who contributed dosimetric data and tables. All authors read and approved the final manuscript.

Acknowledgments
The study was supported by Liaoning province science and technology plan projects, project number: 2012225016.

Author details
1Department of Radiation Oncology, The First Hospital of China Medical University, No.155 Nanjing Road, Heping District, Shenyang 110001, China.
2Department of Nursing, China Medical University, Shenyang 110001, China.

Received: 31 March 2014 Accepted: 23 July 2014
Published: 30 July 2014

Table 5 Multivariate logistic regression analysis of factors associated with RP

| Variables                        | Grade ≥ 2 OR 95% CI       | Grade ≥ 3 OR 95% CI       |
|---------------------------------|--------------------------|--------------------------|
| Age (≥70/<70)                   | 1.99 (1.04-3.80)         | 8.90 (3.23-24.51)        |
| Chemotherapy schedule (concurrent DP/concurrent NP/sequential) | 1.45 (1.01-2.07)         | 1.98 (1.16-3.39)         |
| Response (PR + CR/others)       | 1.06 (0.53-2.14)         | 4.39 (1.12-17.24)        |
| PTV                             | 1.004 (1.002-1.007)      | 1.005 (1.001-1.009)      |
| MLD                             | 1.42 (1.28-1.58)         | 1.64 (1.40-1.93)         |
| Stage (IIIA/IIIB)               | 1.28 (0.72-2.26)         | 0.85 (0.36-2.01)         |
| CTV location (left/right)       | 0.75 (0.43-1.32)         | 1.43 (0.60-3.44)         |
| CTV location (upper/lower)      | 0.68 (0.33-1.40)         | 0.74 (0.25-2.18)         |

RP, radiation pneumonitis; PTV, planning target volume; MLD, mean lung dose; CR, complete response; PR, partial response; DP, docetaxel/cisplatin; NP, vinorelbine/cisplatin; CTV, clinical target volume.
References

1. Dillman RO, Herndon J, Seagren SL, Eaton WT, Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:2120–1215.

2. Le Chevalier T, Arriagada R, Quoix E, Ruffieux P, Martin M, Doubillard J, Tarayre M, Lacome-Tenzer M, Laplanche A: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 335 patients. J Natl Cancer Inst 1991, 83:417–423.

3. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Dang.

4. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machray T, Sause W, Cox J, Dang.

5. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Dang.

6. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr: Consolidation docetaxel after concurrent chemoradiotherapy in locally advanced non-small-cell Lung cancer: groupe Lyon-Saint-Etienne d’Oncologie thoracique-groupe francais de pneumo-Cancérologie: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell Lung cancer: groupe Lyon-Saint-Etienne d’Oncologie thoracique-groupe francais de pneumo-Cancérologie NPC 95–01 study. J Clin Oncol 2005, 23:9590–9517.

7. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machray T, Sause W, Cox J, Dang.

8. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell Lung cancer: a randomized phase II trial. J Clin Oncol 2010, 28:2181–2190.

9. Gandara DR, Chansky K, Albain KS, Le Treut J, Silvis JA, Dansin E, Bozonnat MC, Dauvres JP, Morrox F, Pérol M, Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: a randomized phase III trial RT0G 9410. J Natl Cancer Inst 2011, 103:1452–1460.

10. Auperin A, Le Chevalier T, Arriagada R, Quoix E, Ruffieux P, Martin M, Doubillard J, Tarayre M, Lacome-Tenzer M, Laplanche A, Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 335 patients. J Natl Cancer Inst 1991, 83:417–423.

11. Phernambucq EC, Spoelstra FO, Verbakel WF, Postmus PE, Melissant CF, Dang.

12. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Chen J, Du X, Zheng Y, Qiu G: Improved survival in stage III non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. J Cancer Res Clin Oncol 2010, 136:169–171.

13. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petriss L, Sitt L, Rodrigues G: Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013, 85:444–450.

14. Sunyach MP, Falchero L, Pommier P, Perol D, Arpin D, Vincent M, Boutry D, Rebaut P, Ginestet C, Martel-Lafay I, Perol D, Carie C: Prospective evaluation of early lung toxicity following three-dimensional conformal radiotherapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol Biol Phys 2000, 48:959–963.

15. Gardar DR, Chansky K, Alain BS, Leaigh BR, Gaspar LE, Lara PN, Jr, Burris H, Gunerlock P, Kuebler JP, Bearden JD III, Crowley J, Livingston R, Southwest Oncology Group: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer: phase II southwest oncology group study 99504. J Clin Oncol 2003, 21:2009–2010.

16. Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J, Du X, Zheng Y, Qiu G: Comitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer. Lung Cancer 2011, 72:327–332.

17. Bastos BR, Hatoum GF, Walker GS, Tolba K, Talita C, Gomez J, Santos ES, Lopes G, Ribeiro LE: Efficacy and toxicology of chemoradiotherapy with carboplatin and etoposide followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol 2010, 5:533–540.

18. Erolug C, Dharan O, Usai D, Dogu GG, Karmak H, Dikilitas M, Oztkar A, Oszman M, Kaplan A: Concurrent chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer. Ann Thorac Med 2013, 8:109–115.

19. Phemambucq EC, Spoelstra FO, Verbakel WF, Postmus PE, Melissant CF, van den Brink X, Frings V, van de Ven MP, Smit EF, Senan S: Outcomes of concurrent chemoradiotherapy in patients with stage IIB non-small-cell lung cancer and significant comorbidity. Ann Oncol 2011, 22:132–138.

20. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Chen J, Du X, Zheng Y, Qiu G: Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy and three-dimensional conformal radiotherapy (3D-CRT), Int J Radiat Oncol Biol Phys 2006, 66:1399–1407.

21. Onishi H, Kuriyama K, Yamanagi M, Korniyama T, Tanaka S, Araki T, Nishikawa K, Ishihara H: Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003, 40:79–84.

22. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: International association for the study of lung cancer international staging committee; participating institutions. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:706–714.

23. Dang J, Li G, Lu YB, Yao L, Zhang S, Yu Z: A analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. J Cancer Res Clin Oncol 2010, 136:169–171.

24. Cho KS, Dang J, Kim Y, Park H, Lee J, Kim YH, Kim JH, Seo JY, Kim J, Kim JH, Kim JH: Risk of radiation pneumonitis following thoracic radiotherapy (3D-CRT). J Thorac Oncol 2010, 5:799–803.

25. Sunyach MP, Falchero L, Pommier P, Perol D, Arpin D, Vincent M, Boutry D, Rebaut P, Ginestet C, Martel-Lafay I, Perol D, Carie C: Prospective evaluation of early lung toxicity following three-dimensional conformal radiotherapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol Biol Phys 2000, 48:959–963.

26. Gardar DR, Chansky K, Alain BS, Leaigh BR, Gaspar LE, Lara PN, Jr, Burris H, Gunerlock P, Kuebler JP, Bearden JD III, Crowley J, Livingston R, Southwest Oncology Group: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer: phase II southwest oncology group study 99504. J Clin Oncol 2003, 21:2009–2010.